Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 2,509 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Ischemic Stroke
Interventions: Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase); Drug
Lead sponsor: Andrew D. Barreto, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypogonadism
Interventions: Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex; Combination Product · Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Goserelin, Enzalutamide, mpMRI; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: carboplatin, estramustine, paclitaxel, radiation therapy, leuprolide or goserelin acetate; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 23
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Worcester, Massachusetts + 12 more

Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure; Drug · Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Prostatic Neoplasms
Interventions: Abemaciclib, Darolutamide, LHRH agonist/antagonist; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Springdale, Arkansas • Mineola, New York • New York, New York

Conditions: Sarcoma
Interventions: filgrastim, carboplatin, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth
Interventions: Ameluz 10% Topical Gel, Protoporphyrin IX; Drug · Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: COVID-19
Interventions: hAd5-S-Fusion+N-ETSD vaccine; Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: El Segundo, California • Newport Beach, California

Conditions: Leukoplakia, Erythroplakia
Interventions: PDL-585, ScleroPLUS laser, 5-Aminolevulinic Acid (Levulan KerastickTM), Fluorescence Diagnosis Imaging; Device · Drug · Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Leukemia
Interventions: Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: rituximab, agatolimod sodium; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatitis, Diabetes Mellitus
Interventions: Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin; Diagnostic Test · Genetic · Other + 1 more
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 21 Years
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia
Interventions: busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvespimycin hydrochloride; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection
Interventions: Hyperbaric Oxygen, Hyperbaric Air/Oxygen, Normobaric oxygen; Drug · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Sarcoma
Interventions: filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, mesna, conventional surgery, brachytherapy, intraoperative radiation therapy, radioisotope therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2013
U.S. locations: 220
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 169 more

Conditions: Colitis
Interventions: Vancomycin, Saline; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Severe Periodontitis, Acute Inflammatory Response
Interventions: Customized acrylic mouthguard; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Kidney Diseases
Interventions: DM199; Drug
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Mesa, Arizona • Granada Hills, California • Los Angeles, California + 10 more

Conditions: Septic Shock
Interventions: corticotropin; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: Tulmimetostat, Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 22
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Healthy Volunteers
Interventions: Secretin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 15 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Leukemia, Lymphoma
Interventions: anti-thymocyte globulin, melphalan, antiviral therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

Treatment of Oral Premalignant Lesions With 5-ALA PDT

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Imaging Biomarkers of Pancreatic Function and Disease

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

IFI16 is a Periodontitis Modulating Protein

Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)

Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer